Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Lipids, Inflammation Linked to Multiple Myeloma Origins

March 1st 2016

Madhav Dhodapkar, MBBS, discusses research showing that nflammation and chronic stimulation of the immune system by lipids may trigger multiple myeloma in approximately one-third of all cases.

Expert Hails Ixazomib Approval as “Huge Advance” in Multiple Myeloma

February 4th 2016

Philippe Moreau, MD, discusses the significance of ixazomib and the TOURMALINE-MM1 study, as well as the benefit of an oral regimen for the treatment of patients with relapsed multiple myeloma.

Dr. Voorhees on Triplet Regimen in Multiple Myeloma

February 3rd 2016

Peter Voorhees, MD, associate professor, School of Medicine, University of North Carolina (UNC)-Chapel Hill, Clinical Research, Leukemia, Lymphoma, and Myeloma Program, UNC Lineberger Comprehensive Cancer Center, discusses the triplet regimen of pomalidomide, dexamethasone, and ixazomib in patients with double refractory multiple myeloma.

Getting to Zero: MRD Yardstick for Myeloma Inches Closer

January 29th 2016

Researchers and oncologists are excited about the prospect of MRD becoming equally useful in the assessment and management of patients with multiple myeloma, particularly in light of the development of new, more effective therapies and the current limited ability to assess their effectiveness.

FDA Approval in Myeloma, Expanded Approval in Melanoma, GI Cancer Symposium Highlights, and More

January 28th 2016

FDA Approves Carfilzomib Combo for Relapsed Multiple Myeloma

January 21st 2016

The FDA has approved carfilzomib (Kyprolis) in combination with dexamethasone or with lenalidomide plus dexamethasone for patients with relapsed/refractory multiple myeloma following prior treatment with 1 to 3 lines of therapy

Continuing Anti PD-1 Therapy Beyond RECIST Progression

January 12th 2016

Latest Advances in Multiple Myeloma Treatment

January 12th 2016

Potential Role of Daratumumab in Multiple Myeloma

January 12th 2016

FDA Labels of New Multiple Myeloma Agents

January 12th 2016

Using Pomalidomide in Multiple Myeloma

January 12th 2016

Applying New Multiple Myeloma Agents to Practice

January 12th 2016

Elotuzumab and Ixazomib in Multiple Myeloma

January 12th 2016

Significance of the ENDEAVOR Trial in Multiple Myeloma

January 12th 2016

Managing Relapsed Disease in Multiple Myeloma

January 12th 2016

Consolidation and Maintenance Therapy in Multiple Myeloma

January 12th 2016

Transplant-Eligible Patients in Multiple Myeloma

January 12th 2016

Treating Multiple Myeloma in Elderly Populations

January 12th 2016

Treatment Regimens for Transplant Ineligible Myeloma

January 12th 2016

Managing Smoldering Myeloma

January 12th 2016